Everything in this track so far has been about equity. But the average venture-backed startup in 2026 has more than equity on its balance sheet — it has venture debt, revenue-based financing, receivables credit, R&D tax-credit loans, equipment leases, and a half-dozen other non-equity instruments stacked on top of the equity stack. The case for these instruments is structural: each one funds something specific without diluting the founder. This module walks through what they are, when they fit, and what the 2023 SVB collapse changed about all of them.
The previous seven modules have been almost entirely about equity. That's appropriate — equity is the structurally interesting part of venture finance, and the part most foreign to people coming from corporate-finance backgrounds. But it would be a mistake to leave students with the impression that "raising money" and "raising equity" are synonyms. They aren't, and the difference matters more in 2026 than it did even five years ago.
The argument for non-equity financing is straightforward: every dollar of debt or revenue-based financing is a dollar of equity you don't have to sell. A company that funds its $5M of growth via debt instead of an equity round preserves whatever its current equity ownership is. If the company eventually doubles in value, that preserved equity is worth 2× what it would be if it had been sold to fund the growth. The math is exactly the founder-dilution math from Module 02 working in reverse: the more capital comes from non-equity sources, the less the founders need to dilute themselves.
Equity is patient capital with no fixed repayment obligation, in exchange for permanent ownership. Debt is impatient capital with a fixed obligation, but no ownership transfer. Revenue-based financing is in between — repayment is tied to actual performance rather than a fixed schedule, but the cost is not equity. The art is matching the right instrument to the right use of funds. Equity is the right instrument for the work that might fail; debt and revenue-financing are the right instruments for the work that won't.
The reason most early-stage startups don't use much non-equity financing is that they're not creditworthy in the conventional sense — the same structural reasons banks don't lend to startups, from Module 01, mostly still apply. A two-person company with no revenue cannot borrow against future profits because there are no future profits to credibly point at. Non-equity financing therefore tends to enter the picture after a company has raised initial equity, has revenue, and has demonstrated some kind of repeatable business — at which point a specific subset of its capital needs can be met by instruments that don't require selling more shares.
For a typical Series B-stage company, the practical non-equity options on the table are venture debt, revenue-based financing, receivables and working-capital lines, R&D tax-credit financing, and equipment-specific debt. The remaining sections walk through each.
Venture debt is the original non-equity instrument for venture-backed startups. The model dates from the 1980s and was pioneered in the U.S. by Silicon Valley Bank — a regional bank that built a specialized practice lending to startups that traditional banks wouldn't touch. SVB's collapse in March 2023 reshaped the market substantially (Section 04 covers what happened), but the instrument itself remains widely used.
A venture-debt loan is structured as a term loan with an interest rate, a repayment schedule, and a maturity. On top of the standard debt terms, the lender receives warrants — options to buy the company's preferred stock at the most recent round's price, exercisable for 7-10 years. The warrants give the lender some upside if the company does well, on top of the interest income; they typically cover 5-15% of the loan amount in warrant value.
Venture debt typically becomes available after a company has raised at least a Series A from a recognized venture firm. The lender's underwriting case rests less on the company's own creditworthiness — which is usually weak — and more on the credibility of the equity investors behind it. The implicit assumption: if the company runs into trouble, the equity investors will support it through another round, ensuring the debt gets repaid. This is the structural foundation of venture debt, and it's what made SVB's role distinctive (and what made its collapse so consequential).
Venture debt is best deployed to extend a company's runway without taking another equity round. Common uses:
Revenue-based financing (RBF) is a newer category that emerged in the 2010s and grew rapidly through the 2020s. The model: the lender provides capital upfront, and the company repays it as a fixed percentage of monthly revenue until a fixed total has been paid back. There is no fixed schedule; the repayment timing scales with the business.
An RBF advance of $1M might be structured as: company repays 5% of monthly revenue until $1.3M total has been paid. If the company does $2M of revenue in the first year, that year's repayment is $100K, and at that pace the advance is repaid in about 3 years. If the company grows faster, repayment is faster and the effective cost per dollar borrowed is lower; if it grows slower, repayment is slower and the cost is higher.
The structure makes RBF naturally suited to businesses with predictable monthly revenue — subscription SaaS, e-commerce, content platforms, marketplaces with transaction fees. It's poorly suited to businesses with lumpy revenue (enterprise sales with annual contracts), businesses pre-revenue (no base to take a percentage of), or businesses where the revenue is highly correlated with risk factors the RBF lender doesn't want exposure to.
From the founder's perspective, RBF is attractive for three reasons: no dilution, no fixed monthly payment that strains cash in slow periods, and no covenants on company decisions. The cost — typically 20-50% effective IRR on the lent capital — is higher than bank debt but lower than equity in most growth scenarios.
From the lender's perspective, RBF is essentially a portfolio play on revenue. The lender funds many companies, expects some to grow fast (yielding high returns), some to grow slowly (yielding poor returns), and some to fail (yielding losses). The portfolio returns are designed to look like high-yield credit rather than venture — somewhere between bank lending and venture capital on the risk-return curve.
For nearly four decades, Silicon Valley Bank was the dominant lender to U.S. venture-backed startups. By 2022, SVB held an estimated 50% of all U.S. venture-debt loans outstanding, plus deposits from roughly half of all U.S. venture-backed companies. The bank's collapse in March 2023 was the second-largest bank failure in U.S. history and reshaped the venture-debt market substantially.
The mechanical cause was textbook: SVB had taken in unusually large deposits during the 2020-2021 venture boom, invested heavily in long-duration Treasury and mortgage bonds, and faced losses when rising interest rates compressed those bond prices. When word spread that the bank was selling bonds at a loss to meet withdrawal requests, depositors — many of them venture-backed companies coordinating through their VC networks — pulled their deposits within hours. The bank failed on March 10, 2023. The FDIC took it over the same day.
The federal government guaranteed all deposits (including those above the $250K FDIC limit) within 48 hours, which prevented widespread payroll failures and corporate-payment chaos. HSBC bought the UK arm. First Citizens acquired SVB's U.S. assets. The shock was contained, but the venture-banking landscape was permanently changed.
Three structural realities became visible:
The venture-debt market didn't disappear — it fragmented. HSBC Innovation Banking (the rebranded UK SVB unit) and First Citizens (which absorbed SVB's U.S. operations) continued offering some venture debt. Specialty lenders that had been smaller — Hercules Capital, Stride Funding, Trinity Capital, TriplePoint Capital — expanded their market share. Some entirely new entrants appeared. By 2025, the market had largely re-formed but with more dispersed lenders, higher pricing, and more conservative terms.
The least glamorous but most widely used non-equity financing for venture-backed companies is short-term working-capital financing — factoring, receivables-based credit, and supplier financing. These instruments are older than venture capital itself, but they're surprisingly well-suited to certain types of startups.
A factor or receivables lender advances cash against unpaid customer invoices, getting repaid when the customer pays. For B2B companies with creditworthy customers and 30-90 day payment terms, factoring converts that working-capital lag into immediate cash without affecting equity. The cost is modest in absolute terms (1-3% per invoice cycle) and the instrument scales naturally with the business.
A specialized form of receivables financing for SaaS companies. The lender extends a credit line based on the company's contracted ARR — the math: if you have $5M ARR and the lender will advance 4 months of it, you can borrow up to $1.67M. Repayment is typically structured as a percentage of monthly revenue, similar to RBF. Pipe, Capchase, and Arc Technologies are the best-known specialized providers.
Often overlooked: many suppliers offer payment terms of 30-90 days, which effectively means the supplier is financing the buyer's inventory or services for that period. For hardware, e-commerce, and physical-product startups, negotiating favorable supplier terms can be one of the cheapest forms of working capital available. The "cost" is usually built into pricing or zero, and there's no lender to negotiate with — just supplier relationships.
These instruments rarely fund the work that defines a venture-backed company — the R&D, the engineering, the experiments. But they reliably fund the working capital that supports a real business: inventory, customer payment lags, operational float. A B2B SaaS company with $10M ARR might have $1-2M of receivables financing against its outstanding invoices, lowering its equity capital need by exactly that amount without changing the equity stack at all.
A category that's bigger outside the U.S. than inside it: borrowing against future R&D tax-credit refunds. Most developed economies offer some form of R&D tax credit to companies investing in research and development. The credits are paid annually, often months after they're earned. Several lenders advance capital against the expected credit refund, providing immediate cash that effectively bridges the timing gap.
The United Kingdom has historically had one of the most generous R&D tax credit schemes (SME R&D Tax Credit), in which small companies can recover roughly 20-30% of qualifying R&D spending as a cash refund. For a UK startup spending £2M on engineers and research, that's potentially £400-600K in refund credits — material capital that would otherwise sit in the future. UK lenders like Liberis, Outfund, and several specialty firms advance against these credits, typically at 70-85% of the expected refund amount.
France has the Crédit d'Impôt Recherche (CIR), a similarly generous R&D tax-credit scheme. French startups benefit from the credit, and several local lenders provide bridge financing against it. The CIR is one of the structural reasons French deep-tech startups have been able to fund longer R&D timelines than equivalent companies in less-supportive tax regimes.
Canada has SR&ED (Scientific Research and Experimental Development), which has historically been the most generous R&D tax credit system in North America. Canadian startups regularly use SR&ED-secured financing, and several specialty Canadian lenders have built businesses around it.
The United States has R&D tax credits but they are less generous and harder to monetize. The U.S. equivalent — the Research and Experimentation Tax Credit (R&E Credit) — produces smaller refunds than the international schemes, and the market for R&D-credit financing is correspondingly smaller. Most U.S. startups can claim some R&D credit but few lenders specialize in advancing against it the way UK and Canadian firms do.
Capital-intensive startups — hardware companies, biotech, climate tech, AI infrastructure firms — have access to specialty debt instruments tied to specific assets. The pattern: the lender takes a security interest in the asset itself, which makes the loan easier to underwrite than general venture debt because the lender has a fallback if the company fails.
The common pattern across these instruments: they fund the asset, not the company. That distinction makes the underwriting simpler than venture debt and the cost lower. The trade-off is that they don't fund the work that makes the startup interesting — they fund the infrastructure that supports it.
To make the discussion concrete, imagine Pipework (our running example) is post-Series A and needs an additional $5M of capital to fund 12 more months of operation before raising a Series B. The naive approach is to raise another equity round. The sophisticated approach is to assemble a non-equity stack that meets the same need with much less dilution.
From Module 07's cap table: Pipework just closed its $15M Series A at a $75M post-money valuation. The company has $2M ARR growing 200% YoY, 25 employees, and a clear path to $5M ARR within 12 months. The Series B is 18-24 months out at an expected valuation of $200-300M post-money. The founders each own 25.7%; the seed investor owns 15.1%; the Series A investor owns 20%; the option pool is 12%.
The company needs $5M of additional capital before the Series B. The naive approach: raise a $5M bridge from existing investors at flat-up valuation, taking another ~6% combined dilution from the founders. Let's see how the same $5M might be raised non-equity instead.
Suppose Pipework instead assembles the $5M from a mix of non-equity sources:
| Source | Amount | Cost / Terms | Dilution |
|---|---|---|---|
| Venture debt | $3.0M | Prime + 5%, 36-month term, 8% warrant coverage | ~0.3% (warrants) |
| Receivables line | $1.0M | 4 months ARR, ~8% effective cost | 0% |
| R&D credit advance | $0.5M | 80% of next year's expected credit, 12% effective cost | 0% |
| Equipment financing | $0.5M | Lease against server infrastructure, 7% rate | 0% |
| Total non-equity | $5.0M | Blended cost: ~10% effective IRR | ~0.3% (warrants only) |
The non-equity stack saves the founders ~2.7 percentage points of dilution. At a Series B valuation of $250M, that's $6.75M of additional value to the founders combined, or about $3.4M each. At a $1B IPO, it's $27M combined.
The cost of the non-equity stack — roughly $500K/year of interest plus the operational complexity of multiple lender relationships — is real but modest relative to the dilution savings. For a company on a credible path to a meaningful Series B, the non-equity approach is mathematically superior provided the company can comfortably service the debt without distress.
The conditional matters. A company that takes on $3M of venture debt and then misses its Series B raise entirely is in much worse trouble than one that took an equity bridge instead. Debt forces a binary: either the next equity round happens and the debt rides through to be repaid, or the company faces real distress. Equity bridges absorb the same money without that binary risk.
Non-equity financing makes sense when the company is on a highly credible path to a meaningful next milestone — either profitability or a clear next equity round at a higher valuation. It is dangerous when the path is uncertain. Founders who match the right instrument to the right confidence level take less dilution; founders who treat all financing the same end up with either too much dilution or too much debt-induced distress.
Six questions on non-equity instruments, the post-SVB venture-debt market, and the trade-off between dilution and the cost of carrying debt.